Long-term effects of oral contraceptives on ovarian cancer risk

被引:74
作者
Bosetti, C
Negri, E
Trichopoulos, D
Franceschi, S
Beral, V
Tzonou, A
Parazzini, F
Greggi, S
La Vecchia, C
机构
[1] Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Ctr Canc Prevent, Boston, MA 02115 USA
[4] Int Agcy Res Canc, Unit Field & Intervent Studies, F-69372 Lyon, France
[5] Radcliffe Infirm, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford OX2 6HE, England
[6] Univ Athens, Sch Med, Dept Hyg & Epidemiol, GR-11527 Athens, Greece
[7] Univ Milan, Prima Clin Ostetr & Ginecol, Milan, Italy
[8] Fdn Senatore Pascale, Div Ostetr & Ginecol, Ist Studio & Cura Tumori, Naples, Italy
[9] Univ Milan, Ist Stat Med & Biometria, I-20122 Milan, Italy
关键词
ovarian cancer; oral contraceptive; case-control study;
D O I
10.1002/ijc.10696
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several epidemiologic studies have reported a protective effect of oral contraceptives (OCs) on ovarian cancer. However, there remain open issues, including better quantification of time-related factors such as time since last use, age at first use and time since first use. We performed a collaborative reanalysis of 6 case-control studies conducted between 1978 and 1999 in the United Kingdom, Greece and Italy, including a total of 2,768 incident, histologically confirmed cases of epithelial ovarian cancer and 6,274 hospital controls under age 70 years. A reduced risk of ovarian cancer was found for ever- compared to never-users [odds ratio (OR) = 0.66, 95% confidence interval (0) 0.56-0.79], and a stronger reduction was observed for women who had used OCs for greater than or equal to5 years (OR = 030, 95% Cl 0.33-0.76) compared to those who had used them for <5 years. The protective effect of OCs on ovarian cancer was consistent across strata of age, parity, menopausal status and family history of breast or ovarian cancer. After allowance for duration of use, no other time factor was related to ovarian cancer risk: the reduced risk was similar for women who stopped OC use greater than or equal to20 years before compared to < 10 years; likewise, no significant modification of risk reduction was observed for age at first OC use and time since first OC use. The present analysis indicates that, after taking into account duration of OC use, the OC protection from ovarian cancer persists for a long time after stopping use. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:262 / 265
页数:4
相关论文
共 29 条
[1]   Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study [J].
Beral, V ;
Hermon, C ;
Kay, C ;
Hannaford, P ;
Darby, SA ;
Reeves, G .
BRITISH MEDICAL JOURNAL, 1999, 318 (7176) :96-100
[2]   RISK-FACTORS FOR OVARIAN-CANCER - A CASE CONTROL STUDY [J].
BOOTH, M ;
BERAL, V ;
SMITH, P .
BRITISH JOURNAL OF CANCER, 1989, 60 (04) :592-598
[3]  
BRESLOW NE, 1990, STAT METHODS CANC RE, V1
[4]  
*CASH, 1987, NEW ENGL J MED, V316, P650
[5]   Reproductive and hormonal factors and ovarian cancer [J].
Chiaffarino, F ;
Pelucchi, C ;
Parazzini, F ;
Negri, E ;
Franceschi, S ;
Talamini, R ;
Conti, E ;
Montella, M ;
La Vecchia, C .
ANNALS OF ONCOLOGY, 2001, 12 (03) :337-341
[6]   FACTORS AFFECTING THE ASSOCIATION OF ORAL-CONTRACEPTIVES AND OVARIAN-CANCER [J].
CRAMER, DW ;
HUTCHISON, GB ;
WELCH, WR ;
SCULLY, RE ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (17) :1047-1051
[7]   POOLED ANALYSIS OF 3 EUROPEAN CASE-CONTROL STUDIES OF EPITHELIAL OVARIAN-CANCER .3. ORAL-CONTRACEPTIVE USE [J].
FRANCESCHI, S ;
PARAZZINI, F ;
NEGRI, E ;
BOOTH, M ;
LAVECCHIA, C ;
BERAL, V ;
TZONOU, A ;
TRICHOPOULOS, D .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (01) :61-65
[8]   Declining ovarian cancer rates in US women in relation to parity and oral contraceptive use [J].
Gnagy, S ;
Ming, EE ;
Devesa, SS ;
Hartge, P ;
Whittemore, AS .
EPIDEMIOLOGY, 2000, 11 (02) :102-105
[9]   Risk factors for ovarian cancer in central Italy [J].
Greggi, S ;
Parazzini, F ;
Paratore, MP ;
Chatenoud, L ;
Legge, F ;
Mancuso, S ;
La Vecchia, C .
GYNECOLOGIC ONCOLOGY, 2000, 79 (01) :50-54
[10]  
*IARC, 1999, MON EV CARC RISK HUM, V72